Skip to main content
×
Home
    • Aa
    • Aa

Targeting the hypoxia-inducible factor (HIF) pathway in cancer

  • Evon Poon (a1), Adrian L. Harris (a2) and Margaret Ashcroft (a1)
Abstract

The central component of hypoxia sensing in the cell is the hypoxia-inducible factor (HIF) transcriptional complex. HIF activity is deregulated in many human cancers, especially those that are highly hypoxic. Hypoxic tumour cells are usually resistant to radiotherapy and most conventional chemotherapeutic agents, rendering them highly aggressive and metastatic. Overexpression of HIF-α, the regulatory subunit of HIF, is associated with increased vascular density, severity of tumour grade, treatment failure and a poor prognostic outcome with conventional therapies. Therefore HIF is an attractive, although challenging, therapeutic target, and several different strategies have been developed to target HIF directly or indirectly in recent years. This review outlines the preclinical and clinical advances in this arena and discusses which cancers may benefit from HIF-targeted therapy.

Copyright
Corresponding author
*Corresponding author: Margaret Ashcroft, Centre for Cell Signalling and Molecular Genetics, University College London, Division of Medicine, Rayne Building, 5 University Street, London, WC1E 6JJ, UK. Tel: +44 (0)20 7679 6205; Fax: +44 (0)20 7679 6211; E-mail: m.ashcroft@ucl.ac.uk
References
Hide All
1Vaupel P., Hockel M. and Mayer A. (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxidants and Redox Signalling 9, 1221-1235
2Hockel M. et al. (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology 26, 45-50
3Hockel M. et al. (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 56, 4509-4515
4Hockel M. et al. (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Research 59, 4525-4528
5Hockel M. and Vaupel P. (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93, 266-276
6Hockel M. et al. (1993) Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecologic Oncology 51, 141-149
7Wang G.L. et al. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America 92, 5510-5514
8Guillemin K. and Krasnow M.A. (1997) The hypoxic response: huffing and HIFing. Cell 89, 9-12
9Semenza G.L. (2003) Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3, 721-732
10Bos R. et al. (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Journal of the National Cancer Institute 93, 309-314
11Zhong H. et al. (1999) Overexpression of hypoxia-inducible factor-1alpha in common human cancers and their metastases. Cancer Research 59, 5830-5835
12Maxwell P.H. et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America 94, 8104-8109
13Staab A. et al. (2007) Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer 7, 213
14Williams K.J. et al. (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology 75, 89-98
15Moeller B.J. et al. (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441
16Moeller B.J. et al. (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99-110
17Jiang B.H. et al. (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. Journal of Biological Chemistry 271, 17771-17778
18Li H., Ko H.P. and Whitlock J.P. (1996) Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha. Journal of Biological Chemistry 271, 21262-21267
19Fukuda R. et al. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry 277, 38205-38211
20Laughner E. et al. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology 21, 3995-4004
21Huang L.E. et al. (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America 95, 7987-7992
22Ivan M. et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468
23Jaakkola P. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472
24Masson N. et al. (2001) Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO Journal 20, 5197-5206
25Yu F. et al. (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 98, 9630-9635
26Bruick R.K. and McKnight S.L. (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340
27Epstein A.C. et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54
28Berra E. et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO Journal 22, 4082-4090
29Kallio P.J. et al. (1998) Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha EMBO Journal 17, 6573-6586
30Wang G.L. and Semenza G.L. (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 90, 4304-4308
31Hewitson K.S. et al. (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. Journal of Biological Chemistry 277, 26351-26355
32Lando D. et al. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes and Development 16, 1466-1471
33Lando D. et al. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861
34McNeill L.A. et al. (2002) Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. The Biochemical Journal 367, 571-575
35Mahon P.C., Hirota K. and Semenza G.L. (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes and Development 15, 2675-2686
36Semenza G.L. (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology 15, 551-578
37Bardos J.I. and Ashcroft M. (2005) Negative and positive regulation of HIF-1: a complex network. Biochimica et Biophysica Acta 1755, 107-120
38Wiesener M.S. et al. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92, 2260-2268
39Carroll V.A. and Ashcroft M. (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Research 66, 6264-6270
40Compernolle V. et al. (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nature Medicine 8, 702-710
41Hu C.J. et al. (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Molecular and Cellular Biology 23, 9361-9374
42Krieg M. et al. (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-5443
43Raval R.R. et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology 25, 5675-5686
44Maxwell P.H. et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275
45Maynard M.A. et al. (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. Journal of Biological Chemistry 278, 11032-11040
46Makino Y. et al. (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414, 550-554
47Makino Y. et al. (2007) Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. Journal of Biological Chemistry 282, 14073-14082
48Briere J.J. et al. (2006) Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. American Journal of Physiology – Cell Physiology 291, C1114-1120
49Pollard P.J. et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Human Molecular Genetics 14, 2231-2239
50Berra E., Pages G. and Pouyssegur J. (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer and Metastasis Reviews 19, 139-145
51Karni R. et al. (2002) Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. Journal of Biological Chemistry 277, 42919-42925
52Lee B.L. et al. (2008) A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis 29, 44-51
53Zhong H. et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research 60, 1541-1545
54Bardos J.I. and Ashcroft M. (2004) Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26, 262-269
55Zundel W. et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development 14, 391-396
56Miyake K. et al. (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36, e1-9
57Koukourakis M.I. et al. (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 53, 1192-1202
58Winter S.C. et al. (2006) The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107, 757-766
59Aebersold D.M. et al. (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 61, 2911-2916
60Bos R. et al. (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97, 1573-1581
61Gruber G. et al. (2004) Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Research 6, R191-198
62Klatte T. et al. (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clinical Cancer Research 13, 7388-7393
63Osada R. et al. (2007) Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Human Pathology 38, 1310-1320
64Ke H.L. et al. (2008) Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. International Journal of Urology 15, 200-205
65Talks K.L. et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. American Journal of Pathology 157, 411-421
66Fillies T. et al. (2005) HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5, 84
67Sumiyoshi Y. et al. (2006) Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clinical Cancer Research 12, 5112-5117
68Maxwell P.H. (2005) The HIF pathway in cancer. Seminars in Cell and Developmental Biology 16, 523-530
69Bastien L. et al. (2009) Targeted therapies in metastatic renal cancer in 2009. BJU International 103, 1334–42
70Yeo E.J., Chun Y.S. and Park J.W. (2004) New anticancer strategies targeting HIF-1. Biochemical Pharmacology 68, 1061-1069
71Chen J. et al. (2003) Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. American Journal of Pathology 162, 1283-1291
72Zinzalla G. and Thurston D.E. (2009) Targeting protein–protein interactions for therapeutic intervention: a challenge for the future. Future Medicinal Chemistry 1, 65-93
73Kung A.L. et al. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Medicine 6, 1335-1340
74Kung A.L. et al. (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6, 33-43
75Li S.H. et al. (2008) A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Molecular Cancer Therapeutics 7, 3729-3738
76Yeo E.J. et al. (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute 95, 516-525
77Park E.J. et al. (2006) Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 5, 1847-1853
78Erez N. et al. (2003) Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Research 63, 8777-8783
79Choi H.J. et al. (2008) Rapid degradation of hypoxia-inducible factor-1alpha by KRH10 2053, a new activator of prolyl hydroxylase 2. British Journal of Pharmacology 154, 114-125
80Nakayama K. et al. (2004) Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 117, 941-952
81Moller A. et al. (2009) Inhibition of Siah ubiquitin ligase function. Oncogene 28, 289-296
82Soussi T. and Lozano G. (2005) p53 mutation heterogeneity in cancer. Biochemical and Biophysical Research Communications 331, 834-842
83Levine A.J. (1997) p53 the cellular gatekeeper for growth and division. Cell 88, 323-331
84Vousden K.H. and Lane D.P. (2007) p53 in health and disease. Nature Reviews Molecular Cell Biology 8, 275-283
85Denko N.C. et al. (2000) p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia. Experimental Cell Research 258, 82-91
86Giaccia A.J. and Kastan M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes and Development 12, 2973-2983
87Graeber T.G. et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91
88An W.G. et al. (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392, 405-408
89Blagosklonny M.V. et al. (1998) p53 inhibits hypoxia-inducible factor-stimulated transcription. Journal of Biological Chemistry 273, 11995-11998
90Ravi R. et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes and Development 14, 34-44
91Yang J. et al. (2009) Small molecule activation of p53 blocks HIF-1{alpha} and VEGF expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Molecular and Cellular Biology 29, 2243-2253
92Sanchez-Puig N., Veprintsev D.B. and Fersht A.R. (2005) Binding of natively unfolded HIF-1alpha ODD domain to p53. Molecular Cell 17, 11-21
93Schmid T. et al. (2004) p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). The Biochemical Journal 380, 289-295
94Chen D. et al. (2003) Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. Journal of Biological Chemistry 278, 13595-13598
95Nieminen A.L. et al. (2005) Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. Journal of Cellular Physiology 204, 364-369
96Bykov V.J. and Wiman K.G. (2003) Novel cancer therapy by reactivation of the p53 apoptosis pathway. Annals of Medicine 35, 458-465
97Foster B.A. et al. (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510
98Issaeva N. et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Medicine 10, 1321-1328
99Vassilev L.T. (2004) Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3, 419-421
100Chau N.M. et al. (2005) Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Research 65, 4918-4928
101Tan C. et al. (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Research 65, 605-612
102Rapisarda A. et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Research 62, 4316-4324
103Rapisarda A. et al. (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Research 64, 6845-6848
104Koh M.Y. et al. (2008) Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 7, 90-100
105Macpherson G.R. and Figg W.D. (2004) Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biology and Therapy 3, 503-504
106Welsh S. et al. (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 3, 233-244
107Manabe H. et al. (2008) Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflammation Research 57, 4-10
108Mie Lee Y. et al. (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochemical and Biophysical Research Communications 300, 241-246
109Sasakawa Y. et al. (2003) Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Letters 195, 161-168
110Sasakawa Y. et al. (2003) Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochemical Pharmacology 66, 897-906
111Yang Q.C. et al. (2006) Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. Journal of Experimental and Clinical Cancer Research 25, 593-599
112Alqawi O., Moghaddas M. and Singh G. (2006) Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer and Prostatic Diseases 9, 126-135
113Isaacs J.S. et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. Journal of Biological Chemistry 277, 29936-29944
114Kim W.Y. et al. (2009) Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Research 69, 1624-1632
115Lang S.A. et al. (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clinical Cancer Research 13, 6459-6468
116Liu Y.V. et al. (2007) RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Molecular Cell 25, 207-217
117Zhang H. et al. (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America 105, 19579-19586
118Gordan J.D. et al. (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335-347
119Gordan J.D. et al. (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446
120Chen H.H. et al. (2007) Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Research and Treatment 103, 167-175
121Hara S. et al. (2006) Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncology 42, 593-598
122Hayashi M. et al. (2005) Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension. Endocrinology 146, 4682-4689
123Lim J.H. et al. (2004) Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 23, 9427-9431
124Giles R.H. et al. (2006) Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene 25, 3065-3070
125Jiang Y. et al. (2007) Hypoxia induces transforming growth factor-beta1 gene expression in the pulmonary artery of rats via hypoxia-inducible factor-1alpha. Acta Biochimica et Biophysica Sinica (Shanghai) 39, 73-80
126Kaidi A., Williams A.C. and Paraskeva C. (2007) Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nature Cell Biology 9, 210-217
127Covello K.L., Simon M.C. and Keith B. (2005) Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Research 65, 2277-2286
128Hu C.J. et al. (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Molecular and Cellular Biology 26, 3514-3526
129Sowter H.M. et al. (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Research 63, 6130-6134
130Rankin E.B. et al. (2008) Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27, 5354-5358
131Silva P. et al. (2008) Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. International Journal of Radiation Oncology Biology Physics 72, 1551-1559
132Tzao C. et al. (2008) Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Disease Markers 25, 141-148
133Uehara M. et al. (2009) Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncology 45, 241-246
134Trastour C. et al. (2007) HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. International Journal of Cancer 120, 1451-1458
135Motzer R.J. et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 356, 115-124
136Motzer R.J. et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24, 16-24
137Ratain M.J. et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24, 2505-2512
138O'Brien M.F., Russo P. and Motzer R.J. (2008) Sunitinib therapy in renal cell carcinoma. BJU International 101, 1339-1342
139Turcotte S. et al. (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14, 90-102
140Bommi-Reddy A. et al. (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen. Proceedings of the National Academy of Sciences of the United States of America 105, 16484-16489
141Doll C.M. et al. (2003) Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients. International Journal of Radiation Oncology Biology Physics 55, 1239-1246
142Movsas B. et al. (2001) Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. American Journal of Clinical Oncology 24, 458-461
143Kaanders J.H. et al. (2002) Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Research 62, 7066-7074
144Evans S.M. et al. (2000) Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Research 60, 2018-2024
145Raleigh J.A. et al. (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Research 58, 3765-3768
146Brahme A. (2003) Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncologica 42, 123-136
147Padhani A.R. et al. (2007) Imaging oxygenation of human tumours. European Radiology 17, 861-872
148Rajendran J.G. and Krohn K.A. (2005) Imaging hypoxia and angiogenesis in tumors. Radiologic Clinics of North America 43, 169-187
149Gagel B. et al. (2006) [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6, 51
150Rajendran J.G. et al. (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clinical Cancer Research 12, 5435-5441
151Thorwarth D. et al. (2006) Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiotherapy and Oncology 80, 151-156
152Troost E.G. et al. (2008) Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging 35, 1803-1811
153Hendriksen E.M. et al. (2009) Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvascular Research 77, 96-103
154Kong D. et al. (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Research 65, 9047-9055
155Jones D.T. and Harris A.L. (2006) Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Molecular Cancer Therapeutics 5, 2193-2202
156Lin X. et al. (2008) A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proceedings of the National Academy of Sciences of the United States of America 105, 174-179
157Lee K. et al. (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proceedings of the National Academy of Sciences of the United States of America 106, 2353-2358
158Greenberger L.M. et al. (2008) A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Molecular Cancer Therapeutics 7, 3598-3608
159Dikmen Z.G. et al. (2008) In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 104, 985-994
160McEvoy L.M. et al. (2005) HIF oligonucleotide decoy molecules. US Patent 056795
161Buchler P. et al. (2004) Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 100, 201-210
162Sandau K.B., Faus H.G. and Brune B. (2000) Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochemical and Biophysical Research Communications 278, 263-267
163Sandau K.B. et al. (2001) Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. Journal of Biological Chemistry 276, 39805-39811
164Wang B. et al. (2005) Genistein inhibited hypoxia-inducible factor-1alpha expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Methods and Findings in Experimental and Clinical Pharmacology 27, 179-184
165Calvani M. et al. (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Research 68, 285-291
166Lu Y. et al. (2007) Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Molecular Cancer 6, 63
167Luwor R.B. et al. (2005) The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24, 4433-4441
168Pore N. et al. (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Research 66, 3197-3204
169Alam H. et al. (2009) Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone. Endocrinology 150, 915-928
170Sutton K.M. et al. (2007) Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 26, 3920-3929
171Kumar S.M. et al. (2007) Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Research 67, 3177-3184
172Pore N. et al. (2006) Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Research 66, 9252-9259
173Pore N. et al. (2006) HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 8, 889-895
174Garcia-Maceira P. and Mateo J. (2009) Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28, 313-324
175Stewart G.D. et al. (2009) NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. International Journal of Cancer 124, 223-232
176Pencreach E. et al. (2009) Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clinical Cancer Research 15, 1297-1307
177Wang W. et al. (2008) Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Digestive Diseases and Sciences >Dec 4; [Epub ahead of print]
178Wan X. et al. (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8, 394-401
179Cejka D. et al. (2008) Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biology and Therapy 7, 1377-1385
180Mabuchi S. et al. (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clinical Cancer Research 13, 4261-4270
181Fang J. et al. (2007) Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28, 858-864
182Liu L.Z. et al. (2005) Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Molecular Pharmacology 68, 635-643
183Mirzoeva S. et al. (2008) Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Molecular Carcinogenesis 47, 686-700
184Osada M., Imaoka S. and Funae Y. (2004) Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Letters 575, 59-63
185Kim H.L. et al. (2006) A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. International Journal of Oncology 29, 255-260
186Lau C.K. et al. (2006) Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochemical and Biophysical Research Communications 348, 1443-1448
187Sun H.L. et al. (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26, 3941-3951
188Zhao Q. et al. (2007) Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 34, 242-247
189Huang S.P. et al. (2005) Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. Journal of Biomedical Science 12, 229-241
190Jones M.K. et al. (2002) von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB Journal 16, 264-266
191Zhong H., Willard M. and Simons J. (2004) NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer 112, 585-595
192Palayoor S.T., Tofilon P.J. and Coleman C.N. (2003) Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clinical Cancer Research 9, 3150-3157
193Fath D.M. et al. (2006) Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. Journal of Biological Chemistry 281, 13612-13619
194Qian D.Z. et al. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Research 64, 6626-6634
195Thomas S.L. et al. (2008) EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7, 2409-2417
196Mabjeesh N.J. et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375
197Mooberry S.L. (2003) Mechanism of action of 2-methoxyestradiol: new developments. Drug Resistance Updates 6, 355-361
198Ricker J.L. et al. (2004) 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clinical Cancer Research 10, 8665-8673
199LaVallee T.M. et al. (2008) Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Molecular Cancer Therapeutics 7, 1472-1482
200Moser C. et al. (2008) ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 8, 206
201Kim H.S. et al. (2008) Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production. Pharmacology 81, 317-324
202Vlaminck B. et al. (2007) Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS Journal 274, 5533-5542
203Olenyuk B.Z. et al. (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of America 101, 16768-16773
204Duyndam M.C. et al. (2007) Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochemical Pharmacology 74, 191-201
205LaRusch G.A. et al. (2007) Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Research 67, 450-454
206Jordan B.F. et al. (2005) Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR in Biomedicine 18, 430-439
207Jordan B.F. et al. (2005) Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7, 475-485
208Palayoor S.T. et al. (2008) PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. International Journal of Cancer 123, 2430-2437
209Werno C., Zhou J. and Brune B. (2008) A23187, ionomycin and thapsigargin upregulate mRNA of HIF-1alpha via endoplasmic reticulum stress rather than a rise in intracellular calcium. Journal of Cellular Physiology 215, 708-714
210Zhu K. et al. (2009) Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Research 69, 1836-1843
211Rapisarda A. and Melillo G. (2007) UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway. Oncogene 26, 6875-6884
212Puppo M. et al. (2008) Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Molecular Cancer Therapeutics 7, 1974-1984
213Creighton-Gutteridge M. et al. (2007) Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clinical Cancer Research 13, 1010-1018
214Kamiyama H. et al. (2005) Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. Journal of Cancer Research and Clinical Oncology 131, 205-213
215Maeda M. et al. (2006) Inhibition of angiogenesis and HIF-1alpha activity by antimycin A1. Biological and Pharmaceutical Bulletin 29, 1344-1348
216Hagen T. et al. (2003) Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302, 1975-1978
217Xia C. et al. (2007) Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Research 67, 10823-10830
218Welsh S.J. et al. (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapeutics 2, 235-243
219Groot A.J. et al. (2008) Conditional inactivation of HIF-1 using intrabodies. Cellular Oncology 30, 397-409
220Yasui H. et al. (2008) Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. British Journal of Cancer 99, 1442-1452
221Zeng L. et al. (2008) TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Science 99, 2327-2335
222Wu H. et al. (2008) Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomedicine and Pharmacotherapy 62, 613-621
223Newcomb E.W. et al. (2005) Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-Oncology 7, 225-235
Davis D.W., Herbst R.S. and Abbruzzese J.L., eds (2008) Antiangiogenic Cancer Therapy, CRC Press
http://www.cancer.gov (US National Cancer Institute)
http://www.cancer.org.uk (Cancer Research UK)
http://www.oncolink.org (web-based cancer resource, University of Pennsylvania, USA)
http://www.icr.ac.uk/ (The Institute of Cancer Research, UK)
http://www.ucl.ac.uk/cancer/ (UCL Cancer Institute, UK)
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 18
Total number of PDF views: 113 *
Loading metrics...

Abstract views

Total abstract views: 713 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd October 2017. This data will be updated every 24 hours.